Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004448 · ClinicalTrials.gov registry record · Phase 2
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00004448 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 96 participants.
The verdict
NCT00004448, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe immunoglobulin A nephropathy.
Interventions
- DRUG Placebo
- DRUG prednisone
- DRUG omega-3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 1997-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004448
The ClinicalTrials.gov registry entry for NCT00004448 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00004448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004448 about?
NCT00004448 is a clinical study titled "Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy". OBJECTIVES: Evaluate the efficacy of alternate day prednisone versus daily fish oil supplements in slowing or preventing the decline in renal function in children, adolescents, and young adults with moderate to severe immunoglobulin A nephropathy.
What is the current status of trial NCT00004448?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 1997-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00004448?
The interventions under investigation include: Placebo (DRUG), prednisone (DRUG), omega-3 fatty acids (DRUG).
Who is sponsoring clinical trial NCT00004448?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.